Ammonia N-13

Ammonia N-13

Ammonia N-13 Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Ammonia N 13 Injection USP is indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease.

History

There is currently no drug history available for this drug.

Other Information

11.1 Chemical Characteristics

Ammonia N 13 Injection is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. The active ingredient, [13N] ammonia, has the molecular formula of 13NH3with a molecular weight of 16.03, and has the following chemical structure:image of chemical structure

Ammonia N 13 Injection is provided as a ready to use sterile, pyrogen-free, clear and colorless solution.  Each mL of the solution contains between 0.138 GBq to 1.387 GBq (3.75 mCi to 37.5mCi) of [13N] ammonia, at the end of synthesis (EOS) reference time, in 0.9% aqueous sodium chloride.  The pH of the solution is between 4.5 to 7.5. The recommended dose of radioactivity (10-20 mCi) is associated with a theoretical mass dose of 0.5-1.0 picomoles (8.47-16.94 picograms) of ammonia.

11.2 Physical Characteristics

Nitrogen N13 decays by emitting positron to Carbon C13 (stable) and has a physical half-life of 9.96 minutes.  The principal photons useful for imaging are the dual 511 keV gamma photons that are produced and emitted simultaneously in opposite direction when the positron interacts with an electron (Table 2).

Table 2: Principal Radiation Emission Data for Nitrogen 13
Radiation/Emission%Per DisintegrationEnergy
*
Produced by positron annihilation
Positron(β+)1001190 keV (Max.)
Gamma(±)*200511 keV

The specific gamma ray constant (point source air kerma coefficient) for nitrogen N13 is 5.9 R/hr/mCi (1.39 x 10-6 Gy/hr/kBq) at 1 cm.  The half-value layer (HVL) of lead (Pb) for 511 keV photons is 4 mm. Selected coefficients of attenuation are listed in Table 3 as a function of lead shield thickness. For example, the use of 39 mm thickness of lead will attenuate the external radiation by a factor of about 1000.

Table 3: Radiation Attenuation of 511 keV Photons by lead (Pb) shielding
Shield Thickness (Pb) mmCoefficient of Attenuation
40.5
80.25
130.1
260.01
390.001
520.0001

Table 4 lists fractions remaining at selected time intervals from the calibration time.  This information may be used to correct for physical decay of the radionuclide.

Table 4: Physical Decay Chart for Nitrogen N 13
MinutesFraction Remaining
*
Calibration time
0*1.000
50.706
100.499
150.352
200.249
250.176
300.124

Ammonia N-13 Manufacturers


  • Brigham And Women’s Hospital, Inc., The
    Ammonia N-13 Injection [Brigham And Women’s Hospital, Inc., The]
  • Precision Nuclear Llc
    Ammonia N-13 Injection, Solution [Precision Nuclear Llc]
  • Cardinal Health 414, Llc
    Ammonia N-13 Injection [Cardinal Health 414, Llc]

Login To Your Free Account